Eli Lilly Raises 2026 Revenue Outlook to $85B-$87B on Strong Drug Demand
Guidance·2 articles across 2 outlets·↩ Updated
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Eli Lilly has raised its 2026 revenue guidance to between $85 billion and $87 billion, up from a previous estimate of $82 billion to $85 billion. This adjustment follows a stronger-than-expected second-quarter performance driven by high demand for its weight-loss and diabetes drugs, particularly Mounjaro and Zepbound.
The company's revenue surged by 48%, attributed to the increased sales of its GLP-1 drugs for Type 2 diabetes and weight loss. Analysts had anticipated lower demand, but the results exceeded expectations, prompting the upward revision in sales guidance.
Eli Lilly
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.”
CNBC — Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge“Eli Lilly & Co. raised its 2026 sales guidance after it reported far stronger second-quarter demand than analysts expected for its weight-loss and diabetes drugs.”
Bloomberg — Lilly Boosts Guidance on Strong Demand for Obesity Drugs“Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.”
MarketWatch — Lilly's revenue soars 48%, driven by demand of its GLP-1s
Earlier versions
- Aug 5, 10:57 AM — Eli Lilly Raises 2026 Revenue Outlook to $85B-$87B on Strong Zepbound and Mounjaro Sales (1/1)